Leggi di piùRepligen Corporation (NASDAQ:RGEN) – The Gastrointestinal Drugs Advisory Committee will meet on May 31, 2012 to discuss the new drug application (NDA) 200-436, synthetic human secretin, proposed for use with magnetic resonance imaging (MRI) to improve pancreatic duct visualization for the detection of duct abnormalities to enhance clinical decision making in patients with known or suspected pancreatitis.
Dobry weekend dla czytelników z Polski
Continua il mio diabolico piano per farmi invitare in luoghi interessanti per le ferie. Oggi affido il mio saluto gli amici che da qualche tempo si connettono dalla Polonia alle parole del traduttore automatico di mamma Microsoft. Spero di non scrivere nulla di...Leggi di piùpensare che Merck avesse avuto modo di vedere i risultati prima della loro diffusione non fu affatto difficile…
Leggi di piùEASL plans to selectively distribute hepatitis C drug research abstracts to these folks on Thursday. The same documents will not be made available to the public. That means a select group of investors will have access to potentially stock-moving clinical data while a majority of investors will be kept in the dark.
Journalists registered to cover the EASL meeting will also be granted early access to hepatitis C research abstracts but they are barred by EASL’s restrictive embargo rules from writing about any new data until the start of the April meeting. A. Feuerstein